Literature DB >> 15640775

Impact of SPECT and integrated low-dose CT after radioiodine therapy on the management of patients with thyroid carcinoma.

Juri Ruf1, Lukas Lehmkuhl, Helga Bertram, Dirk Sandrock, Holger Amthauer, Beatrice Humplik, Dieter Ludwig Munz, Roland Felix.   

Abstract

AIM: To determine the value of single photon emission computed tomography (SPECT) with integrated low-dose computed tomography (CT) for the interpretation of inconclusive foci in planar I whole-body scans after radioiodine therapy.
METHODS: Twenty-five patients with inconclusive findings in planar scanning after ablative radioiodine therapy (3.7 GBq I) due to differentiated thyroid cancer were included. SPECT/CT of the region in question was performed with the Millennium VG Hawkeye (GE Medical Systems). SPECT with and without CT fusion were evaluated by two blinded independent nuclear medicine physicians in a consensus reading (including visual plausibility control). Each focus was judged according to its topographical assignment and clinical interpretation. With regard to therapeutic relevance, this information was evaluated in a focus based and patient based analysis. All evaluations used a binary ranking system. Focus assignments were compared to clinical and imaging follow-up.
RESULTS: Forty-one lesions were observed in 25 patients. According to follow-up, 17/41 (41%) foci were caused by thyroid residue, 13/41 (32%) were caused by metastases, and 11/41 (27%) were not malignant. Of these foci, a SPECT/CT consensus reading assigned 39 (95%) correctly, as fused images of two foci did not pass the visual plausibility control (excluding one patient due to misregistration). For the remaining 39 foci, improved anatomical assignment by SPECT/CT was seen in 17/39 (44%) cases.
CONCLUSIONS: The changed interpretation of 15/39 (38%) foci would have been relevant for therapy in the focus based analysis. In the patient based analysis the information was still therapeutically relevant in 6/24 (25%) patients. Furthermore, plausibility control is also crucial in SPECT/CT image fusion in order to rule out artifacts.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15640775     DOI: 10.1097/00006231-200412000-00004

Source DB:  PubMed          Journal:  Nucl Med Commun        ISSN: 0143-3636            Impact factor:   1.690


  25 in total

1.  Endocrine radionuclide scintigraphy with fusion single photon emission computed tomography/computed tomography.

Authors:  Ka-Kit Wong; Arpit Gandhi; Benjamin L Viglianti; Lorraine M Fig; Domenico Rubello; Milton D Gross
Journal:  World J Radiol       Date:  2016-06-28

Review 2.  Technological development and advances in single-photon emission computed tomography/computed tomography.

Authors:  Youngho Seo; Carina Mari; Bruce H Hasegawa
Journal:  Semin Nucl Med       Date:  2008-05       Impact factor: 4.446

Review 3.  Sentinel node navigation surgery for gastric cancer: Overview and perspective.

Authors:  Masakazu Yashiro; Tasuku Matsuoka
Journal:  World J Gastrointest Surg       Date:  2015-01-27

4.  Mediastinal ectopic benign colloid goitre detected using iodine-131 whole body scintigraphy and single-photon emission computed tomography-computed tomography.

Authors:  Koramadai Karuppusamy Kamaleshwaran; Firoz Rajan; Premkumar Asokumar; Vyshak Mohanan; Ajit Sugunan Shinto
Journal:  Indian J Nucl Med       Date:  2015 Apr-Jun

5.  Differentiated thyroid carcinoma: Incremental diagnostic value of 131I SPECT/CT over planar whole body scan after radioiodine therapy.

Authors:  Valentina Zilioli; Alessia Peli; Maria Beatrice Panarotto; Giancarlo Magri; Ahmed Alkraisheh; Christiane Wiefels; Carlo Rodella; Raffaele Giubbini
Journal:  Endocrine       Date:  2016-09-29       Impact factor: 3.633

6.  Single photon emission computed tomography/spiral computed tomography fusion imaging for the diagnosis of bone metastasis in patients with known cancer.

Authors:  Zhen Zhao; Lin Li; Fanglan Li; Lixia Zhao
Journal:  Skeletal Radiol       Date:  2010-02       Impact factor: 2.199

7.  [SPECT/CT for staging and treatment monitoring in oncology. Applications in differentiated thyroid cancer and liver tumors].

Authors:  K Weber; F Berger; M Mustafa; M F Reiser; P Bartenstein; A Haug
Journal:  Radiologe       Date:  2012-07       Impact factor: 0.635

Review 8.  Value of ¹³¹I SPECT/CT for the evaluation of differentiated thyroid cancer: a systematic review of the literature.

Authors:  Yan-Li Xue; Zhong-Ling Qiu; Hong-Jun Song; Quan-Yong Luo
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-12-15       Impact factor: 9.236

9.  Utility of Iodine-131 hybrid SPECT-CT fusion imaging before high-dose radioiodine therapy in papillary thyroid carcinoma.

Authors:  Anish Bhattacharya; Sunil Hejjaji Venkataramarao; Chandra Sekhar Bal; Bhagwant Rai Mittal
Journal:  Indian J Nucl Med       Date:  2010-01

10.  Five months' follow-up of patients with and without iodine-positive lymph node metastases of thyroid carcinoma as disclosed by (131)I-SPECT/CT at the first radioablation.

Authors:  Daniela Schmidt; Rainer Linke; Michael Uder; Torsten Kuwert
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-11-20       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.